DETECTION OF INTERLEUKIN-1-BETA AND INTERLEUKIN-6 IN HUMAN MULTIPLE-MYELOMA BY FLUORESCENT INSITU HYBRIDIZATION

被引：8

作者：

BAKKUS, MHC

BRAKELVANPEER, KMJ

ADRIAANSEN, HJ

VANDENAKKER, TW

BENNER, R

机构：

[1] Department of Immunology, Erasmus University Rotterdam and Academic Hospital, Rotterdam-Dijkzigt, Holland

来源：

LEUKEMIA & LYMPHOMA | 1991年 / 4卷 / 5-6期

关键词：

INSITU HYBRIDIZATION; IL-1-BETA; IL-6; MULTIPLE MYELOMA;

D O I：

10.3109/10428199109068091

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Using fluorescent in situ hybridization together with cell surface marker staining, we studied the expression of mRNA of IL-6 and mRNA of IL-1β in bone marrow samples from human multiple myeloma patients. It is known that IL-6 can stimulate B cell growth and differentiation and recently it has been suggested that IL-6 is responsible for autocrine growth stimulation of myeloma cells and that IL-1 may play a role in bone resorption. These interleukins have previously been detected in the supernatants of cultured myeloma cells. Here we report the expression of IL-1β mRNA by plasma cells, T cells and macrophages according to morphology and immunologic marker analysis, suggesting that not only myeloma cells but other cell types can also contribute to the production of IL-1β and thus to bone-resorption. IL-6 mRNA could not be detected in plasma cells from bone marrow aspirates but were present in monocytes and T cells, suggesting that in vivo IL-6 stimulates the growth of myeloma cells in a paracrine instead of an autocrine way. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：389 / 395

页数：7

共 24 条

[1]

Mellstedt H., Holm G., Bjorklom M., Multiple myeloma, Waldenström’s macroglobulinemia, and benign monoclonal gammapathy: characteristics of the B-cell clone, immunoregulatory cell populations and clinical implications, Adv. Cancer Res, 41, pp. 257-284, (1984)

[2]

Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajiama K., Kishimoto T., The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells, J. Exp. Med, 167, pp. 332-344, (1988)

[3]

Van Damme J., Opdenakker G., Simpson R.J., Rubira M.R., Cayphas S., Vink A., Billiau A., Van Snick J., Identification of the human 26-Kd protein, interferon beta 2 (IFN beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor, J. Exp. Med, 165, pp. 914-919, (1987)

[4]

Poupart P., Vandenbeele P., Cayphas S., Van Snick J., Haegeman G., Kruys V., Fiers W., Content J., B cell growth modulating and differentiating activity of recombinant human 26-Kd protein (BSF-2, HulFN-beta 2, HPGF), EMBO J, 6, pp. 1219-1224, (1987)

[5]

Tosato G., Seamon K.B., Goldman N.D., Seghel F.B., May L.T., Washington G.C., Jones K.D., Pike S.E., Monocyte-derived human B-cell growth factor identified as interferon beta 2 (BSF-2, IL-6), Science, 239, pp. 502-504, (1988)

[6]

Anderson K.C., Jones R.M., Morimoto C., Leavitt P., Barut B.A., Response patterns of purified myeloma cells to hematopoietic growth factors, Blood, 73, pp. 1915-1924, (1989)

[7]

Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T., Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas, Nature, 332, pp. 83-85, (1988)

[8]

Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R., Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors, Nature, 319, pp. 516-518, (1986)

[9]

Dewhirst F.E., Stashenko P.P., Jole J.E., Tsurumachi T., Purification and partial sequence of human osteoclast-activating factor. Identity with interleukin 1β, J. Immunol, 135, pp. 2562-2568, (1985)

[10]

Gowen M., Wood D.D., Ihrie C.J., McGuire M.K.B., Rusell R.G.G., An interleukin-1 like factor stimulates bone resorption in vitro, Nature, 306, pp. 378-380, (1983)

← 1 2 3 →